These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 31358513)

  • 1. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
    Zhang D; Yu SF; Khojasteh SC; Ma Y; Pillow TH; Sadowsky JD; Su D; Kozak KR; Xu K; Polson AG; Dragovich PS; Hop CECA
    Mol Cancer Ther; 2018 Mar; 17(3):677-685. PubMed ID: 29348271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
    Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
    AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
    Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
    AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
    Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
    Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
    Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors.
    Menezes B; Linderman JJ; Thurber GM
    Drug Metab Dispos; 2022 Jan; 50(1):8-16. PubMed ID: 34649966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
    Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
    Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
    Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
    J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
    Sharma S; Li Z; Bussing D; Shah DK
    Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
    Shah DK; Haddish-Berhane N; Betts A
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Lymphocyte Antigen 6 Complex, Locus E-
    Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ
    Drug Metab Dispos; 2020 Dec; 48(12):1247-1256. PubMed ID: 33020064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.